TrialNature communications2025

Anti-PD1 based precision induction therapy in unresectable stage III non-small cell lung cancer: a phase II umbrella clinical trial.

Chengxiang Yi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.